| Metric | Value ($ M) |
|---|---|
| Revenue | 0.23 |
| Total Income | 0.23 |
| Expenditure | 20.29 |
| PBT | -19.27 |
| Net Profit | -19.27 |
| OPM | — |
| NPM | — |
| EPS | -0.09 |
Tenaya Therapeutics Reports Q1 2026 Financial Results
07 May 2026 · 7 May, 1:49 am
Summary
Tenaya Therapeutics announced its financial results for the first quarter ended March 31, 2026. The company's cash and cash equivalents were $80.9 million as of March 31, 2026, and they anticipate funding operations into the second half of 2027 with existing resources and a $10.0 million upfront payment from the Alnylam collaboration. Research and development expenses totaled $14.8 million, while general and administrative expenses were $5.4 million. The net loss for the quarter was $19.3 million, or $0.09 loss per share.
Key Highlights
- 1
Tenaya Therapeutics reported financial results for the first quarter ended March 31, 2026.
- 2
Cash and cash equivalents totaled $80.9 million as of March 31, 2026.
- 3
The company expects cash resources, along with the $10.0 million upfront payment from the Alnylam collaboration, to fund planned operations into the second half of 2027.
- 4
Research and Development expenses were $14.8 million for the first quarter of 2026.
- 5
General and Administrative expenses were $5.4 million for the first quarter of 2026.
- 6
Net loss was $19.3 million, or $0.09 loss per share, for the first quarter ended March 31, 2026.
- 7
Tenaya entered into a multi-target research collaboration with Alnylam Pharmaceuticals, receiving an upfront payment of $10.0M.
Management Comments
Faraz Ali
We are entering a catalyst-rich period for Tenaya, with multiple clinical milestones expected across our lead gene therapy programs throughout 2026. Building on the encouraging initial readouts we reported in 2025, we believe the additional data expected this year from both TN-201 and TN-401 may support alignment on registrational pathways for these novel gene therapies. While our focus remains on the advancement of TN-201 and TN-401 for patients suffering from these genetic cardiomyopathies, we also announced meaningful steps in the direction of our next horizon of opportunities to address unmet patient needs and to create value for stockholders. We presented new preclinical data for TN‑301, our clinical-stage small molecule candidate, in Duchenne muscular dystrophy adding to the body of compelling preclinical evidence for the broad clinical utility of this molecule in multiple prevalent and rare cardiac and cardiac-adjacent indications. Advancing TN‑301 toward a trial in patients reflects our commitment to building a diversified portfolio grounded in mechanistic insight and translational rigor. The recently announced collaboration with Alnylam also reinforces the strength of Tenaya's innovation engine and expands the reach and impact of our modality-agnostic research capabilities.
Informational and educational content only. Not investment advice.